Obesity Medicine

Results of this large study also suggest women with high pericardial fat volume are at greater risk for HF than men, findings that have implications for stratifying prevention and treatment.

Health care providers need to be conscious of the environment they create for patients with obesity or overweight, obesity medicine expert Ethan Lazarus, MD, explains.

New topline data from the global SURPASS-4 trial shows treatment with investigational agent tirzepatide led to superior reductions in A1c and body weight vs insulin glargine.

The links between obesity and cardiovascular disease are many, including direct cause and effect. Click through the 10-slide summary of a new AHA statement for a first look.

ACC.21: High rates of obesity, hypertension, and hyperlipidemia found in Black women in their 20s and 30s are of significant concern, says the author of a study to be presented at the ACC meeting.

ACP 2021: Dr Stephan Moll covers the basics of DOAC duration for VTE, use of anticoagulation in special populations, and perioperative use of DOACs

Research shows that increased risk of chronic disease and mortality begins below a BMI classified as obesity. The earlier we intervene with at-risk patients, the greater the chance for success.

Authors of a new study say their findings suggest bariatric surgery should be considered first-line treatment for the management of obesity in patients with type 2 diabetes.

For frontline clinicians who care daily for patients with obesity and type 2 diabetes, a weight-centric approach to T2D, including antiobesity drugs, could help improve outcomes.

Long time cardiometabolic investigator Harold Bays, MD, talks about obesity, new drugs to treat the disease, and how the words "be inefficient" could change thinking about treatment.

Primary care physicians face unique challenges when managing patients with obesity, but one obesity specialist aims to show clinicians how to meet them, even if it's in small ways.

Citing a study of "The Biggest Loser" participants, obesity expert Dr Silvana Pannain explains why "Eat less, exercise more," often backfires as a sole intervention for persons with obesity.

Keith C Ferdinand, MD, discusses how deeply-rooted social determinants of health have led to the vastly disproportionate impact of COVID-19 on persons of color.

Measures of heart function and anatomy were used to assess the effects of red and processed meat on cardiovascular health; findings were reported at ESC Preventive Cardiology 2021.

Weight loss is known to improve markers of fatty liver disease but authors of a recent meta-analysis took their investigation deeper. Scan through the research to the findings.

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis is increasing and early detection is critical. Brush up on basics with our slides.

Jackson Heart Study participants who maintained a healthy BP, BMI, and never smoked were at lower risk for incident CVD, suggesting targets for intervention in high-risk populations.

In individuals with chronic coronary disease, the presence of diabetes increased the rate of death by 38% during a 5-year follow-up period in analysis of a worldwide patient registry.

Study authors looked for the first time at the impact of bariatric surgery on incidence of all-cause and obesity-related cancer in patients with severe obesity and fatty liver disease.

Asthma of obesity affects more than 10% of men and 14% of women with obesity. Our interview with researcher Anne Dixon, MD, sheds light on this poorly appreciated asthma phenotype.

Obesity medicine specialist, Karli Burridge, PA-C, MMS, discusses how and why physicians can further support and engage patients with obesity through the art of communication.

ENDO 2021: Patients with severe obesity hospitalized for COVID-19 were twice as likely to require ICU admission vs those with normal BMI, according to new findings.

A lifestyle intervention targeting women with obesity and infertility is more effective in increasing the pregnancy rate vs fertility treatments, suggests a new study presented at ENDO 2021.

ENDO 2021: An investigational once-weekly insulin formulation was found as effective as daily basal insulin injection for glucose control with lower rates of hypoglycemia and less weight gain.

ENDO 2021: Obese individuals treated with semaglutide 2.4 mg vs placebo demonstrated improvements in body composition paralleling weight loss that may reduce risk for cardiometabolic disease.